TY - T1的氟喹诺酮类原料药:他们essential to treat multidrug-resistant tuberculosis? JF - European Respiratory Journal JO - Eur Respir J SP - 904 LP - 905 DO - 10.1183/09031936.00159807 VL - 31 IS - 4 AU - Migliori, G. B. AU - Lange, C. AU - Girardi, E. AU - Centis, R. AU - Besozzi, G. AU - Kliiman, K. AU - Codecasa, L. R. AU - Spanevello, A. AU - Cirillo, D. M. AU - the SMIRA/TBNET Study Group Y1 - 2008/04/01 UR - //www.qdcxjkg.com/content/31/4/904.abstract N2 - To the Editors: We read with interest the excellent letter by Holtz and Cegielski 1 contributing to the current discussion on extensively drug-resistant (XDR)-tuberculosis (TB). Several publications have already demonstrated that resistance to fluoroquinolones (FQ) is independently associated with poor outcome and/or that the possibility of including FQ in regimens improves treatment outcomes of multidrug-resistant (MDR)-TB cases 2–4. This happened before the (recent) description of XDR-TB 1, 5. We do not know how many of the patients with MDR-TB strains were, in fact, infected with XDR Mycobacterium tuberculosis. We wanted to establish the role of the different XDR-defining components (e.g. isoniazid and rifampicin, FQ and injectable second-line drugs) in determining poor treatment outcomes. Our group has shown for the first time that XDR-TB cases in Italy and Germany have a five-fold increase in the risk of death (relative risk (RR) 5.45; 95% … ER -